Aprea Therapeutics, Inc.
Aprea Therapeutics, Inc.（APRE）股价预测与分析师目标价
华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。
apre · 股价预测 · 8 位分析师（近3月）· FMP · 更新于 2026年6月9日
分析师评级与共识
基于过去 3 个月内 8 位华尔街分析师
Buy
8 位分析师
共识
评级分布
12 个月目标价
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $0.73
短期股价预测
Low Activity算法生成 · 每日更新
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $0.70 | ↓ 5.00% |
1-day model range: $0.68–$0.71. Peak: $0.71 (-5.00%).
长期股价预测
年度股价预测 · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | — | -50.0% |
| 2028 | — | -62.5% |
| 2029 | — | -67.2% |
| 2030 | — | -69.2% |
| 2031 | — | -70.2% |
基于技术分析的股价预测
14 项技术面信号（SMA×6 + EMA×6 + RSI + MACD）· EEAT 方法论透明
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · APRE · Jun 9, 2026
最新分析师评级与调整
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-05-14 | Wedbush | Maintains | Outperform→Outperform |
| 2026-03-31 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2026-03-31 | Wedbush | Maintains | Outperform→Outperform |
| 2026-02-10 | Wedbush | Maintains | Outperform→Outperform |
| 2026-01-29 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-12-18 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-01-15 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-12-17 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-11-18 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-10-24 | HC Wainwright & Co. | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Aprea Therapeutics, Inc. (APRE) stock. Of the recent 39 rating actions, 0 were upgrades and 4 were downgrades. 8 analysts currently cover APRE.
分析师推荐趋势
APRE analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
财务预测：EPS 与营收一致预期
Revenue This Year
$1M
↓ 73.4% YoY
Revenue Next Year
$2M
↑ 111.5% YoY
EPS This Year
$-0.68
EPS Next Year
$-0.65
↓ 4.4% YoY
EPS ForecastReported vs Estimated
Analysts forecast APRE EPS of $-0.68 for the current fiscal year, based on estimates from 3 analysts. The APRE revenue forecast is $1M for the current year. These are analyst consensus estimates via FMP / S&P Global.
关于预测与目标价
APRE 股价预测由两类独立数据源支撑：来自 8 位华尔街分析师（S&P Global / FMP）的共识评级，以及基于历史日终价计算的技术分析。APRE 的共识目标价为 $0.00（+0.0% 上行空间），分析师共识为 Buy。
APRE 的短期预测（明日）为 $0.70（-5.00%）。 APRE 对 2030 年的预测区间为 $0–$0。
Aprea Therapeutics, Inc. 在 NASDAQ 上市，代码 APRE。APRE 在 2027 年的整体展望偏积极，在覆盖分析师中约 50% 对应 Buy 共识。
常见问题
APRE 预测 · 8 个问题根据 8 位华尔街分析师，APRE 的 12 个月平均目标价为 $0.00，最高 $0.00、最低 $0.00。若有图表，中位目标价可在上方查看。相对当前价 $0.73，隐含约 +0.0% 的上行空间。
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.